Jubilant Pharmova reports Q2 and H1 FY27 financial results and operational updates
Jubilant Pharmova · Pharmaceuticals & Biotechnology
Key highlights
- Q2 FY27 revenue grew 21% YoY to ₹2,370 Cr; H1 FY27 revenue grew 19% YoY to ₹4,599 Cr
- Q2 FY27 EBITDA ₹255 Cr; H1 FY27 EBITDA ₹523 Cr; PAT ₹31 Cr in Q2 and ₹87 Cr in H1; margins declined YoY
- Raised ₹800 Cr via NCDs to refinance debt and fund capex; net debt increased to ₹2,637 Cr as of Sep 30, 2026
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Jubilant Pharmova
- Fundraise / allotmentNotableJubilant Pharmova Allots ₹800 Crore Non-Convertible Debentures on Nov 5, 2026
- Fundraise / allotmentNotableJubilant Pharmova allots ₹800 crore NCDs via private placement on Nov 5, 2026
- Fundraise / allotmentNotableJubilant Pharmova approves issuance of up to ₹800 crore NCDs on private placement
- Order winNotable· Adverse for the businessJubilant Pharmova receives USFDA approval for Line 3 at Spokane facility
- Order winNotable· Adverse for the businessJubilant Pharmova reports USFDA Warning Letter for Montreal contract manufacturing site
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentUnited Heat TransferUnited Heat Transfer Limited approves half-year financial results for Sept 2026
- Fundraise / allotmentNatural CapsulesNatural Capsules Limited approves Q2 2026 results and preferential allotment
- Fundraise / allotmentNatural CapsulesNatural Capsules Ltd announces Q2 FY27 results and approves preferential allotment
- Fundraise / allotmentDestiny Logistics & InfraDestiny Logistics & Infra Ltd announces key resignations, appointments, and warrant lapse
- Fundraise / allotmentShalimar PaintsShalimar Paints Limited announces QIP Committee approval for equity shares issue
- Fundraise / allotmentOrchid PharmaOrchid Pharma Limited QIP proceeds utilization and monitoring report for Q2 FY 2026-27
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.